1 - 5 of 5
1
Conference icon

Conference

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease

  • Keshav, S, Johnson, D, Bekker, P, et al.
  • 2009-05-05
2
Conference icon

Conference

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease

  • Keshav, S, Ungashe, S, Zheng, W, et al.
  • 2007-04-05
3
Conference icon

Conference

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B

  • Ungashe, SB, Wei, Z, Rubas, W, et al.
  • 2008-04-06
4
Journal article icon

Journal article

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.

  • Walters, MJ, Wang, Y, Lai, N, et al.
  • 2010-10-05
5
Conference icon

Conference

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease

  • Keshav, S, Petryka, R, Vanask, T, et al.
  • 2007-09-05
FILTER RESULTS

TO TOP